Vasopressin: A novel target for the prevention and retardation of kidney disease?

Nature Reviews Nephrology

Volumn 9, Issue 4, 2013, Pages 223-239

  Bankir, Lise ^a   Bouby, Nadine ^a   Ritz, Eberhard ^b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b Division Nephrology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; COPEPTIN; CREATININE; DESMOPRESSIN ACETATE; KLOTHO PROTEIN; NITROGEN; PHOSPHATE; POTASSIUM ION; RWJ 677070; SODIUM ION; TERLIPRESSIN; TOLVAPTAN; UNCLASSIFIED DRUG; UREA; URIC ACID; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; YM218;

ALBUMINURIA; ALCOHOL CONSUMPTION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; EXCRETION; FLUID INTAKE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GLOMERULUS FILTRATION RATE; HOST RESISTANCE; HUMAN; HYPERTENSION; HYPONATREMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CONCENTRATING CAPACITY; KIDNEY FUNCTION; KIDNEY PAIN; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; METABOLIC SYNDROME X; NATRIURESIS; NITROGEN URINE LEVEL; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PLASMA OSMOLALITY; POLLAKISURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REVIEW; RISK FACTOR; SMOKING; URINARY TRACT INFECTION; URINE FLOW RATE; URINE OSMOLALITY; URINE VOLUME; UROLITHIASIS;

ANIMALS; BENZAZEPINES; DISEASE PROGRESSION; HUMANS; HYPERTENSION, RENAL; INCIDENCE; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; VASOPRESSINS;

EID: 84875758393     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.22     Document Type: Review

References (216)

1. Addis, T. Glomerular nephritis (The Macmillan Company, New York, 1949).
2. Serradeil-Le Gal, C. et al. Nonpeptide vasopressin receptor antagonists: Development of selective and orally active V1a, V2 and V1b receptor ligands. Prog. Brain Res. 139, 197-210 (2002).
3. Miyazaki, T., Fujiki, H., Yamamura, Y., Nakamura, S. & Mori, T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc. Drug Rev. 25, 1-13 (2007).
4. Greenberg, A. & Verbalis, J. G. Vasopressin receptor antagonists. Kidney Int. 69, 2124-2130 (2006).
5. Torres, V. E. Role of vasopressin antagonists. Clin. J. Am. Soc. Nephrol. 3, 1212-1218 (2008).
6. Decaux, G., Soupart, A. & Vassart, G. Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet 371, 1624-1632 (2008).
7. Morgenthaler, N. G., Struck, J., Alonso, C. & Bergmann, A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin. Chem. 52, 112-119 (2006).
8. Morgenthaler, N. G. Copeptin: A biomarker of cardiovascular and renal function. Congest. Heart Fail. 16 (Suppl. 1), S37-S44 (2010).
9. Morel, A., O'Carroll, A. M., Brownstein, M. J. & Lolait, S. J. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 356, 523-526 (1992).
10. Birnbaumer, M. et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature 357, 333-335 (1992).
11. Zingg, H. H. Vasopressin and oxytocin receptors. Baillieres Clin. Endocrinol. Metab. 10, 75-96 (1996).
12. Bichet, D. G. Vasopressin receptors in health and disease. Kidney Int. 49, 1706-1711 (1996).
13. Boertien, W. E. et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 27, 4131-4137 (2012).
14. Clark, W. F. et al. Urine volume and change in estimated GFR in a community-based cohort study. Clin. J. Am. Soc. Nephrol. 6, 2634-2641 (2011).
15. Meijer, E. et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 88, 561-567 (2009).
16. Meijer, E. et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 361-368 (2011).
17. Meijer, E. et al. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int.77, 29-36 (2010).
18. Strippoli, G. F. et al. Fluid and nutrient intake and risk of chronic kidney disease. Nephrology (Carlton) 16, 326-334 (2011).
19. Torres, V. E. et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 640-647 (2011).
20. Plischke, M., Kohl, M., Handisurya, A. & Haas, M. Association between urine osmolality and progression of chronic renal failure: A cohort study [abstract TH PO322]. J. Am. Soc. Nephrol. 23, 169A (2012).
21. Boertien, W. E. et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: Results from the CRISP cohort. Am. J. Kidney Dis. http://dx.doi.org/10.1053/j.ajkd.2012.08.038.
22. Higashihara, E. et al. Tolvaptan in autosomal dominant polycystic kidney disease: Three years' experience. Clin. J. Am. Soc. Nephrol. 6, 2499-2507 (2011).
23. Pan, A. et al. Plain-water intake and risk of type 2 diabetes in young and middle-aged women. Am. J. Clin. Nutr. 95, 1454-1460 (2012).
24. Roussel, R. et al. Low water intake and risk for new-onset hyperglycemia. Diabetes Care 34, 2551-2554 (2011).
25. Torres, V. E. et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am. J. Kidney Dis. 57, 692-699 (2011).
26. Abbasi, A. et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 55, 1963-1970 (2012).
27. Enhörning, S. et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: The prospective Malmo Diet and Cancer Study cardiovascular cohort. Int. J. Obes. (Lond.) http://dx.doi.org/10.1038/ ijo.2012.88.
28. Enhörning, S. et al. Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am. J. Clin. Nutr. 89, 400-406 (2009).
29. Enhörning, S. et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 121, 2102-2108 (2010).
30. Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407-2418 (2012).
31. Valtin, H. "Drink at least eight glasses of water a day." Really? Is there scientific evidence for "8 × 8"? Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R993-R1004 (2002).
32. Wenzel, U. O., Hebert, L. A., Stahl, R. A. & Krenz, I. My doctor said I should drink a lot! Recommendations for fluid intake in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 1, 344-346 (2006).
33. McCartney, M. Waterlogged? BMJ 343, d4280 (2011).
34. Negoianu, D. & Goldfarb, S. Just add water. J. Am. Soc. Nephrol. 19, 1041-1043 (2008).
35. Hebert, L. A., Greene, T., Levey, A., Falkenhain, M. E. & Klahr, S. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am. J. Kidney Dis. 41, 962-971 (2003).
36. Bouby, N., Bachmann, S., Bichet, D. & Bankir, L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am. J. Physiol. 258, F973-F979 (1990).
37. Sugiura, T. et al. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: Possible role of TGF-beta. Kidney Int. 55, 1800-1810 (1999).
38. Bouby, N., Hassler, C. & Bankir, L. Contribution of vasopressin to progression of chronic renal failure: Study in Brattleboro rats. Life Sci. 65, 991-1004 (1999).
39. Bregman, R., Boim, M. A., Santos, O. F., Ramos, O. L. & Schor, N. Effects of systemic hypertension, antidiuretic hormone, and prostaglandins on remnant nephrons. Hypertension 15, 172-175 (1990).
40. Okada, H., Suzuki, H., Kanno, Y. & Saruta, T. Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats. Nephron 72, 667-672 (1996).
41. Perico, N. et al. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int. 76, 960-967 (2009).
42. Bardoux, P. et al. Vasopressin increases urinary albumin excretion in rats and humans: Involvement of V2 receptors and the renin-angiotensin system. Nephrol. Dial. Transplant. 18, 497-506 (2003).
43. Bardoux, P. et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: Study in vasopressin-deficient Brattleboro rats. Proc. Natl Acad. Sci. USA 96, 10397-10402 (1999).
44. Fernandes, S. et al. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinology 143, 2759-2766 (2002).
45. Bardoux, P., Bruneval, P., Heudes, D., Bouby, N. & Bankir, L. Diabetes-induced albuminuria: Role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol. Dial. Transplant. 18, 1755-1763 (2003).
46. Windt, W. A. et al. Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy. J. Renin Angiotensin Aldosterone Syst. 7, 217-224 (2006).
47. Okada, T. et al. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clin. Exp. Nephrol. 13, 438-446 (2009).
48. Bankir, L. & Kriz, W. Adaptation of the kidney to protein intake and to urine concentrating activity: Similar consequences in health and CRF. Kidney Int. 47, 7-24 (1995).
49. Brenner, B. M. Nephron adaptation to renal injury or ablation. Am. J. Physiol. 249, F324-F337 (1985).
50. Orth, S. R. & Hallan, S. I. Smoking: A risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients-absence of evidence or evidence of absence? Clin. J. Am. Soc. Nephrol. 3, 226-236 (2008).
51. Stack, A. G. & Murthy, B. V. Cigarette use and cardiovascular risk in chronic kidney disease: An unappreciated modifiable lifestyle risk factor. Semin. Dial. 23, 298-305 (2010).
52. Schaeffner, E. & Ritz, E. Alcohol and kidney damage: A Janus-faced relationship. Kidney Int. 81, 816-818 (2012).
53. Stookey, J. D. The diuretic effects of alcohol and caffeine and total water intake misclassification. Eur. J. Epidemiol. 15, 181-188 (1999).
54. Belibi, F. A. et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int. 66, 964-973 (2004).
55. Torres, V. E. Vasopressin antagonists in polycystic kidney disease. Semin. Nephrol. 28, 306-317 (2008).
56. Wang, X., Ward, C. J., Harris, P. C. & Torres, V. E. Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int. 77, 129-140 (2010).
57. Gattone, V. H. 2nd. Emerging therapies for polycystic kidney disease. Curr. Opin. Pharmacol. 5, 535-542 (2005).
58. Gross, P. Polycystic kidney disease: will it become treatable? Pol. Arch. Med. Wewn. 118, 298-301 (2008).
59. Torres, V. E., Bankir, L. & Grantham, J. J. A case for water in the treatment of polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 1140-1150 (2009).
60. Wang, X., Wu, Y., Ward, C. J., Harris, P. C. & Torres, V. E. Vasopressin directly regulates cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 19, 102-108 (2008).
61. Reif, G. A. et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl( ) secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am. J. Physiol. Renal Physiol. 301, F1005-F1013 (2011).
62. Irazabal, M. V. et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int. 80, 295-301 (2011).
63. Wang, C. J., Creed, C., Winklhofer, F. T. & Grantham, J. J. Water prescription in autosomal dominant polycystic kidney disease: A pilot study. Clin. J. Am. Soc. Nephrol. 6, 192-197 (2011).
64. Howl, J. et al. Characterization of the human liver vasopressin receptor. Profound differences between human and rat vasopressin receptor mediated responses suggest only a minor role for vasopressin in regulating human hepatic function. Biochem. J. 276, 189-195 (1991).
65. Ostrowski, N. L. et al. Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain. Endocrinology 131, 533-535 (1992).
66. Serradeil-Le Gal, C. et al. Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes. Biochem. Biophys. Res. Commun. 199, 353-360 (1994).
67. Serradeil-Le Gal, C. et al. Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059. Kidney Int. 50, 499-505 (1996).
68. Folny, V. et al. Pancreatic vasopressin V1b receptors: Characterization in In R1 G9 cells and localization in human pancreas. Am. J. Physiol. Endocrinol. Metab. 285, E566-E576 (2003).
69. Monstein, H. J., Truedsson, M., Ryberg, A. & Ohlsson, B. Vasopressin receptor mRNA expression in the human gastrointestinal tract. Eur. Surg. Res. 40, 34-40 (2008).
70. Oshikawa, S., Tanoue, A., Koshimizu, T. A., Kitagawa, Y. & Tsujimoto, G. Vasopressin stimulates insulin release from islet cells through V1b receptors: A combined pharmacological/knockout approach. Mol. Pharmacol. 65, 623-629 (2004).
71. Richardson, S. B., Laya, T. & VanOoy, M. Similarities between hamster pancreatic islet beta (HIT) cell vasopressin receptors and V1b receptors. J. Endocrinol. 147, 59-65 (1995).
72. Yibchok-Anun, S., Cheng, H., Heine, P. A. & Hsu, W. H. Characterization of receptors mediating AVP-and OT induced glucagon release from the rat pancreas. Am. J. Physiol. 277, E56-E62 (1999).
73. Hems, D. A. & Whitton, P. D. Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. Biochem. J. 136, 705-709 (1973).
74. Martin, G. & Baverel, G. Vasopressin promotes the metabolism of near-physiological concentration of glutamine in isolated rat liver cells. Biosci. Rep. 4, 171-176 (1984).
75. Whitton, P. D., Rodrigues, L. M. & Hems, D. A. Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem. J. 176, 893-898 (1978).
76. Abu-Basha, E. A., Yibchok-Anun, S. & Hsu, W. H. Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 51, 1184-1190 (2002).
77. Spruce, B. A. et al. The effect of vasopressin infusion on glucose metabolism in man. Clin. Endocrinol. (Oxf.) 22, 463-468 (1985).
78. Aoyagi, T. et al. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 148, 2075-2084 (2007).
79. Hiroyama, M. et al. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol. Endocrinol. 21, 247-258 (2007).
80. Hiroyama, M. et al. Hyperammonaemia in V1a vasopressin receptor knockout mice caused by the promoted proteolysis and reduced intrahepatic blood volume. J. Physiol. 581, 1183-1192 (2007).
81. Zerbe, R. L., Vinicor, F. & Robertson, G. L. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 28, 503-508 (1979).
82. Zerbe, R. L., Vinicor, F. & Robertson, G. L. Regulation of plasma vasopressin in insulin-dependent diabetes mellitus. Am. J. Physiol. 249, E317-E325 (1985).
83. Bankir, L., Bardoux, P. & Ahloulay, M. Vasopressin and diabetes mellitus. Nephron 87, 8-18 (2001).
84. Ahloulay, M., Schmitt, F., Dechaux, M. & Bankir, L. Vasopressin and urinary concentrating activity in diabetes mellitus. Diabetes Metab. 25, 213-222 (1999).
85. Enhörning, S. et al. Plasma copeptin, a unifying factor behind the metabolic syndrome. J. Clin. Endocrinol. Metab. 96, E1065-E1072 (2011).
86. Pedersen, M. M., Christiansen, J. S., Pedersen, E. B. & Mogensen, C. E. Determinants of intra-individual variation in kidney function in normoalbuminuric insulin-dependent diabetic patients: Importance of atrial natriuretic peptide and glycaemic control. Clin. Sci. (Lond.) 83, 445-451 (1992).
87. Thibonnier, M. et al. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension 34, 1293-1300 (1999).
88. Thibonnier, M et al. Study of V(1)-vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension. J. Mol. Cell. Cardiol. 32, 557-564 (2000).
89. Bankir, L., Bichet, D. G. & Bouby, N. Vasopressin V2 receptors, ENaC, and sodium reabsorption: A risk factor for hypertension? Am. J. Physiol. Renal Physiol. 299, F917-F928 (2010).
90. Nicco, C. et al. Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung. Hypertension 38, 1143-1149 (2001).
91. Bankir, L. Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc. Res. 51, 372-390 (2001).
92. Kohan, D. E. et al. Uncovering the surprising and complex roles of collecting duct adenylyl cyclases [abstract SA OR073]. J. Am. Soc. Nephrol. 23, 82A (2012).
93. Blanchard, A. et al. Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent. Clin. J. Am. Soc. Nephrol. 6, 753-759 (2011).
94. Bankir, L., Fernandes, S., Bardoux, P., Bouby, N. & Bichet, D. G. Vasopressin V2 receptor stimulation reduces sodium excretion in healthy humans. J. Am Soc. Nephrol. 16, 1920-1928 (2005).
95. Choukroun, G., Schmitt, F., Martinez, F., Drueke, T. B. & Bankir, L. Low urine flow reduces the capacity to excrete a sodium load in humans. Am. J. Physiol 273, R1726-R1733 (1997).
96. Hall, J. E., Montani, J. P., Woods, L. L. & Mizelle, H. L. Renal escape from vasopressin: Role of pressure diuresis. Am. J. Physiol. 250, F907-F916 (1986).
97. Bankir, L., Bardoux, P., Mayaudon, H., Dupuy, O. & Bauduceau, B. Impaired urinary flow rate during the day: A new factor possibly involved in hypertension and in the lack of nocturnal dipping [French]. Arch. Mal. Coeur Vaiss. 95, 751-754 (2002).
98. Bankir, L. et al. Nighttime blood pressure and nocturnal dipping are associated with daytime urinary sodium excretion in African subjects. Hypertension 51, 891-898 (2008).
99. Guerrot, D. et al. Reduced insulin secretion and nocturnal dipping of blood pressure are associated with a disturbed circadian pattern of urine excretion in metabolic syndrome. J. Clin. Endocrinol. Metab. 96, E929-E933 (2011).
100. Zhang, X., Hense, H. W., Riegger, G. A. & Schunkert, H. Association of arginine vasopressin and arterial blood pressure in a population-based sample. J. Hypertens. 17, 319-324 (1999).
101. Bakris, G., Bursztyn, M., Gavras, I., Bresnahan, M. & Gavras, H. Role of vasopressin in essential hypertension: Racial differences. J. Hypertens. 15, 545-550 (1997).
102. Bankir, L., Perucca, J. & Weinberger, M. H. Ethnic differences in urine concentration: Possible relationship to blood pressure. Clin. J. Am. Soc. Nephrol. 2, 304-312 (2007).
103. Cowley, A. W. Jr, Skelton, M. M. & Velasquez, M. T. Sex differences in the endocrine predictors of essential hypertension. Vasopressin versus renin. Hypertension 7, I151-I160 (1985).
104. Bursztyn, M., Bresnahan, M., Gavras, I. & Gavras, H. Pressor hormones in elderly hypertensive persons. Racial differences. Hypertension 15, I88-I92 (1990).
105. Luft, F. C. Vasopressin, urine concentration, and hypertension: A new perspective on an old story. Clin. J. Am. Soc. Nephrol. 2, 196-197 (2007).
106. Young, J. H. et al. Differential susceptibility to hypertension is due to selection during the out of Africa expansion. PLoS Genet. 1, e82 (2005).
107. Ammar, A., Roseau, S. & Butlen, D. Pharmacological characterization of V1a vasopressin receptors in the rat cortical collecting duct. Am. J. Physiol. 262, F546-F553 (1992).
108. Arpin-Bott, M. P. et al. Historadioautographic localization of oxytocin and V1a vasopressin binding sites in the kidney of developing and adult rabbit, mouse and merione and of adult human. Exp. Nephrol. 10, 196-208 (2002).
109. Inoue, T., Nonoguchi, H. & Tomita, K. Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. Cardiovasc. Res. 51, 470-480 (2001).
110. Terada, Y., Tomita, K., Nonoguchi, H., Yang, T. & Marumo, F. Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. J. Clin. Invest. 92, 2339-2345 (1993).
111. Kirschenbaum, M. A., Lowe, A. G., Trizna, W. & Fine, L. G. Regulation of vasopressin action by prostaglandins. Evidence for prostaglandin synthesis in the rabbit cortical collecting tubule. J. Clin. Invest. 70, 1193-1204 (1982).
112. Bonvalet, J. P., Pradelles, P. & Farman, N. Segmental synthesis and actions of prostaglandins along the nephron. Am. J. Physiol. 253, F377-F387 (1987).
113. Schlondorff, D. Renal prostaglandin synthesis. Sites of production and specific actions of prostaglandins. Am. J. Med. 81, 1-11 (1986).
114. Zhang, M. Z., Sanchez Lopez, P., McKanna, J. A. & Harris, R. C. Regulation of cyclooxygenase expression by vasopressin in rat renal medulla. Endocrinology 145, 1402-1409 (2004).
115. Perucca, J., Bichet, D. G., Bardoux, P., Bouby, N. & Bankir, L. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J. Am. Soc. Nephrol. 19, 1721-1731 (2008).
116. Izumi, Y. et al. Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway. Am. J. Physiol. Renal Physiol. 292, F1418-F1426 (2007).
117. Balment, R. J., Brimble, M. J., Forsling, M. L. & Musabayane, C. T. Natriuretic response of the rat to plasma concentrations of arginine vasopressin within the physiological range. J. Physiol. 352, 517-526 (1984).
118. Ando, Y. & Asano, Y. Functional evidence for an apical V1 receptor in rabbit cortical collecting duct. Am. J. Physiol. 264, F467-F471 (1993).
119. Ando, Y., Tabei, K. & Asano, Y. Luminal vasopressin modulates transport in the rabbit cortical collecting duct. J. Clin. Invest. 88, 952-959 (1991).
120. Ikeda, M., Yoshitomi, K., Imai, M. & Kurokawa, K. Cell Ca2+ response to luminal vasopressin in cortical collecting tubule principal cells. Kidney Int. 45, 811-816 (1994).
121. Loichot, C. et al. Vasopressin does not effect hypertension caused by long-term nitric oxide inhibition. Hypertension 35, 602-608 (2000).
122. Nonoguchi, H. et al. Role of urinary arginine vasopressin in the sodium excretion in patients with chronic renal failure. Am. J. Med Sci. 312, 195-201 (1996).
123. Crofton, J. T., Dustan, H., Share, L. & Brooks, D. P. Vasopressin secretion in normotensive black and white men and women on normal and low sodium diets. J. Endocrinol. 108, 191-199 (1986).
124. Wang, Y. X., Crofton, J. T. & Share, L. Sex differences in the cardiovascular and renal actions of vasopressin in conscious rats. Am. J. Physiol. 272, R370-R376 (1997).
125. Bhandari, S. S. et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin. Sci. (Lond.) 116, 257-263 (2009).
126. Share, L., Crofton, J. T. & Ouchi, Y. Vasopressin: Sexual dimorphism in secretion, cardiovascular actions and hypertension. Am. J. Med. Sci. 295, 314-319 (1988).
127. Stachenfeld, N. S., Splenser, A. E., Calzone, W. L., Taylor, M. P. & Keefe, D. L. Sex differences in osmotic regulation of AVP and renal sodium handling. J. Appl. Physiol. 91, 1893-1901 (2001).
128. Perucca, J., Bouby, N., Valeix, P. & Bankir, L. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R700-R705 (2007).
129. O'Donnell, C. J. et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 97, 1766-1772 (1998).
130. Rankinen, T. et al. AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study. Am. J. Physiol. Heart Circ. Physiol. 279, H368-H374 (2000).
131. Stankovic, A., Zivkovic, M. & Alavantic, D. Angiotensin I converting enzyme gene polymorphism in a Serbian population: A gender-specific association with hypertension. Scand. J. Clin. Lab. Invest 62, 469-475 (2002).
132. Wang, J. G. et al. Association between hypertension and variation in the alpha-and beta-adducin genes in a white population. Kidney Int. 62, 2152-2159 (2002).
133. Chassin, C. et al. Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin. J. Exp. Med. 204, 2837-2852 (2007).
134. Bolignano, D. et al. Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor 2 (V2 R). Urol. Oncol. 28, 642-647 (2010).
135. Braver, D. J., Modan, M., Chetrit, A., Lusky, A. & Braf, Z. Drinking, micturition habits, and urine concentration as potential risk factors in urinary bladder cancer. J. Natl Cancer Inst. 78, 437-440 (1987).
136. Tang, C. et al. Downregulation of Klotho expression by dehydration. Am. J. Physiol. Renal Physiol. 301, F745-F750 (2011).
137. Ganio, M. S. et al. Mild dehydration impairs cognitive performance and mood of men. Br. J. Nutr. 106, 1535-1543 (2011).
138. Benton, D. Dehydration influences mood and cognition: A plausible hypothesis? Nutrients 3, 555-573 (2011).
139. Adan, A. Cognitive performance and dehydration. J. Am. Coll. Nutr. 31, 71-78 (2012).
140. Armstrong, L. E. et al. Mild dehydration affects mood in healthy young women. J. Nutr. 142, 382-388 (2012).
141. Patel, A. V., Mihalik, J. P., Notebaert, A. J., Guskiewicz, K. M. & Prentice, W. E. Neuropsychological performance, postural stability, and symptoms after dehydration. J. Athl. Train. 42, 66-75 (2007).
142. Spigt, M. G. et al. Increasing the daily water intake for the prophylactic treatment of headache: A pilot trial. Eur. J. Neurol. 12, 715-718 (2005).
143. Stookey, J. D., Purser, J. L., Pieper, C. F. & Cohen, H. J. Plasma hypertonicity: Another marker of frailty? J. Am. Geriatr. Soc. 52, 1313-1320 (2004).
144. Wilson, M. M. & Morley, J. E. Impaired cognitive function and mental performance in mild dehydration. Eur. J. Clin. Nutr. 57 (Suppl. 2), S24-S29 (2003).
145. Spigt, M. G., Knottnerus, J. A., Westerterp, K. R., Olde Rikkert, M. G. & Schayck, C. P. The effects of 6 months of increased water intake on blood sodium, glomerular filtration rate, blood pressure, and quality of life in elderly (aged 55-75) men. J. Am. Geriatr. Soc. 54, 438-443 (2006).
146. Edmonds, C. J. & Jeffes, B. Does having a drink help you think? 6 7 Year-old children show improvements in cognitive performance from baseline to test after having a drink of water. Appetite 53, 469-472 (2009).
147. Bichet, D. G. Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin. Nephrol. 28, 245-251 (2008).
148. Mizuno, J. & Takeda, N. Phylogenetic study of the arginine-vasotocin/arginine vasopressin like immunoreactive system in invertebrates. Comp. Biochem. Physiol. A Comp. Physiol. 91, 739-747 (1988).
149. Kawada, T., Kanda, A., Minakata, H., Matsushima, O. & Satake, H. Identification of a novel receptor for an invertebrate oxytocin/vasopressin superfamily peptide: Molecular and functional evolution of the oxytocin/vasopressin superfamily. Biochem. J. 382, 231-237 (2004).
150. Stafflinger, E. et al. Cloning and identification of an oxytocin/vasopressin-like receptor and its ligand from insects. Proc. Natl Acad. Sci. USA 105, 3262-3267 (2008).
151. van Kesteren, R. E. et al. Evolution of the vasopressin/oxytocin superfamily: Characterization of a cDNA encoding a vasopressin-related precursor, preproconopressin, from the mollusc Lymnaea stagnalis. Proc. Natl Acad. Sci. USA 89, 4593-4597 (1992).
152. Zerbe, R. L. & Robertson, G. L. Osmoregulation of thirst and vasopressin secretion in human subjects: Effect of various solutes. Am. J. Physiol. 244, E607-E614 (1983).
153. Baylis, P. H. Osmoregulation and control of vasopressin secretion in healthy humans. Am. J. Physiol. 253, R671-R678 (1987).
154. Galanth, C., Hus-Citharel, A., Li, B. & Llorens Cortes, C. Apelin in the control of body fluid homeostasis and cardiovascular functions. Curr. Pharm. Des. 18, 789-798 (2012).
155. Ramsay, D. J. The importance of thirst in maintenance of fluid balance. Baillieres Clin. Endocrinol. Metab. 3, 371-391 (1989).
156. Zerbe, R. L., Miller, J. Z. & Robertson, G. L. The reproducibility and heritability of individual differences in osmoregulatory function in normal human subjects. J. Lab. Clin. Med. 117, 51-59 (1991).
157. Perrier, E. et al. Hydration biomarkers in free-living adults with different levels of habitual fluid consumption. Br. J. Nutr. 1-10 (2012).
158. Andersen, L. J., Andersen, J. L., Schutten, H. J., Warberg, J. & Bie, P. Antidiuretic effect of subnormal levels of arginine vasopressin in normal humans. Am. J. Physiol. 259, R53-R60 (1990).
159. Robertson, G. L. The regulation of vasopressin function in health and disease. Recent Prog. Horm. Res. 33, 333-385 (1976).
160. Schmitt, F. et al. Influence of plasma amino acid level on vasopressin secretion. Diabetes Metab. 29, 352-361 (2003).
161. Bichet, D. G., Arthus, M. F., Barjon, J. N., Lonergan, M. & Kortas, C. Human platelet fraction arginine-vasopressin. Potential physiological role. J. Clin. Invest. 79, 881-887 (1987).
162. Morgenthaler, N. G., Struck, J., Jochberger, S. & Dunser, M. W. Copeptin: Clinical use of a new biomarker. Trends Endocrinol. Metab. 19, 43-49 (2008).
163. Fenske, W. et al. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J. Am. Soc. Nephrol. 22, 782-790 (2011).
164. Howl, J. & Wheatley, M. Molecular pharmacology of V1a vasopressin receptors. Gen. Pharmacol. 26, 1143-1152 (1995).
165. Jard, S. Vasopressin receptors. A historical survey. Adv. Exp. Med. Biol. 449, 1-13 (1998).
166. Walum, H. et al. Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. Proc. Natl Acad. Sci. USA 105, 14153-14156 (2008).
167. Koshimizu, T. A. et al. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol. Rev. 92, 1813-1864 (2012).
168. Akerlund, M. et al. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br. J. Obstet. Gynaecol. 106, 1047-1053 (1999).
169. Grazzini, E. et al. Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes. Adv. Exp. Med. Biol. 449, 325-334 (1998).
170. Thibonnier, M., Snajdar, R. M. & Rapp, J. P. Characterization of vasopressin receptors of rat urinary bladder and spleen. Am. J. Physiol. 251, H115-H120 (1986).
171. Manning, M., Lowbridge, J., Haldar, J. & Sawyer, W. H. Design of neurohypophyseal peptides that exhibit selective agonistic and antagonistic properties. Fed. Proc. 36, 1848-1852 (1977).
172. Manning, M. & Sawyer, W. H. Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J. Recept. Res. 13, 195-214 (1993).
173. Kinter, L. B., Huffman, W. F. & Stassen, F. L. Antagonists of the antidiuretic activity of vasopressin. Am. J. Physiol. 254, F165-F177 (1988).
174. Richardson, D. W. & Robinson, A. G. Desmopressin. Ann. Intern. Med. 103, 228-239 (1985).
175. Saito, M., Tahara, A. & Sugimoto, T. 1 desamino 8 D arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem. Pharmacol. 53, 1711-1717 (1997).
176. Krag, A., Borup, T., Moller, S. & Bendtsen, F. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv. Ther. 25, 1105-1140 (2008).
177. Lebrec, D. Review article: future indications for terlipressin therapy. Aliment. Pharmacol. Ther. 20 (Suppl. 3), 65-67 (2004).
178. Krag, A., Bendtsen, F., Pedersen, E. B., Holstein Rathlou, N. H. & Moller, S. Effects of terlipressin on the aquaretic system: Evidence of antidiuretic effects. Am. J. Physiol. Renal Physiol. 295, F1295-F1300 (2008).
179. Krag, A., Pedersen, E. B., Moller, S. & Bendtsen, F. Effects of the vasopressin agonist terlipressin on plasma cAMP and ENaC excretion in the urine in patients with cirrhosis and water retention. Scand. J. Clin. Lab. Invest. 71, 112-116 (2011).
180. Schrier, R. W. et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 355, 2099-2112 (2006).
181. Palm, C., Pistrosch, F., Herbrig, K. & Gross, P. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am. J. Med. 119, S87-S92 (2006).
182. Verbalis, J. G. AVP receptor antagonists as aquaretics: Review and assessment of clinical data. Cleve. Clin. J. Med. 73 (Suppl. 3), S24-S33 (2006).
183. Farmakis, D., Filippatos, G., Kremastinos, D. T. & Gheorghiade, M. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Curr. Heart Fail. Rep. 5, 91-96 (2008).
184. Aperis, G. & Alivanis, P. Tolvaptan: A new therapeutic agent. Rev. Recent Clin. Trials 6, 177-188 (2011).
185. Ferguson-Myrthil, N. Novel agents for the treatment of hyponatremia: A review of conivaptan and tolvaptan. Cardiol. Rev. 18, 313-321 (2010).
186. Goldsmith, S. R. Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists? Am. J. Med. 119, S93-S96 (2006).
187. Bankir, L. & Trinh Trang Tan, M. M. Urea and the kidney in The Kidney 6th edn (ed. Brenner, B. M.) 637-679 (W. B. Saunders Company, Philadelphia, 2000).
188. Bouby, N. et al. Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J. Am. Soc. Nephrol. 7, 842-851 (1996).
189. Capasso, G. et al. A decrease in renal medullary tonicity stimulates anion transport in Henle's loop of rat kidneys. Am. J. Physiol. 274, F693-F699 (1998).
190. Bankir, L., Martin, H. & Bouby, N. Vasopressin (AVP) increases GFR in rats. Disclosure of this effect was previously obscured by inadequate experimental protocols. FASEB J. 12, A331 (1998).
191. Roald, A. B., Tenstad, O. & Aukland, K. The effect of AVP V2 receptor stimulation on local GFR in the rat kidney. Acta Physiol. Scand. 168, 351-359 (2000).
192. Trinh Trang Tan, M. M., Bouby, N., Doute, M. & Bankir, L. Effect of long-and short-term antidiuretic hormone availability on internephron heterogeneity in the adult rat. Am. J. Physiol. 246, F879-F888 (1984).
193. Bankir, L. et al. Adaptation of the rat kidney to altered water intake and urine concentration. Pflugers Arch. 412, 42-53 (1988).
194. Anastasio, P. et al. Level of hydration and renal function in healthy humans. Kidney Int. 60, 748-756 (2001).
195. Hadj-Aissa, A. et al. Influence of the level of hydration on the renal response to a protein meal. Kidney Int. 42, 1207-1216 (1992).
196. Boertien, W. E. et al. Short-term renal hemodynamic responses and safety of tolvaptan in subjects with ADPKD at various levels of kidney function. [Abstract TH PO632]. J. Am. Soc. Nephrol. 23, 243A (2012).
197. Bangalore, S. et al. J curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur. Heart J. 31, 2897-2908 (2010).
198. Filippone, E. J. & Foy, A. The j curve revisited: A therapeutic dilemma. Cardiol. Rev. 20, 253-258 (2012).
199. Berl, T. Impact of solute intake on urine flow and water excretion. J. Am. Soc. Nephrol. 19, 1076-1078 (2008).
200. Epstein, F. H., Kleeman, C. R. & Hendrikx, A. The influence of bodily hydration on the renal concentrating process. J. Clin. Invest. 36, 629-634 (1957).
201. Yang, B. & Bankir, L. Urea and urine concentrating ability: New insights from studies in mice. Am. J. Physiol. Renal Physiol. 288, F881-F896 (2005).
202. Fenton, R. A. Essential role of vasopressin-regulated urea transport processes in the mammalian kidney. Pflugers Arch. 458, 169-177 (2009).
203. Armsen, T., Glossmann, V., Weinzierl, M. & Edel, H. H. Familial proximal tubular azotemia. Elevated urea plasma levels in normal kidney function [German]. Dtsch Med. Wochenschr. 111, 702-706 (1986).
204. Bankir, L. et al. Is the process of urinary urea concentration responsible for a high glomerular filtration rate? J. Am. Soc. Nephrol. 4, 1091-1103 (1993).
205. Bankir, L., Bouby, N., Trinh Trang Tan, M. M., Ahloulay, M. & Promeneur, D. Direct and indirect cost of urea excretion. Kidney Int. 49, 1598-1607 (1996).
206. D'Apolito, M. et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J. Clin. Invest. 120, 203-213 (2010).
207. Kraus, L. M. & Kraus, A. P. Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int. Suppl. 78, S102-S107 (2001).
208. Vaziri, N. D., Gandotra, G., Moradi, H. & Yuan, J. Central role of urea in disruption of intestinal tight junction and barrier dysfunction in CKD. [Abstract FR PO628]. J. Am. Soc. Nephrol. 23, 514A (2012).
209. Bankir, L. & Yang, B. New insights into urea and glucose handling by the kidney, and the urine concentrating mechanism. Kidney Int. 81, 1179-1198 (2012).
210. Hauben, D. J., Le Roith, D., Glick, S. M. & Mahler, D. Nonoliguric vasopressin oversecretion in severely burned patients. Isr. J. Med. Sci. 16, 101-105 (1980).
211. Loirat, P. et al. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N. Engl. J. Med. 299, 915-919 (1978).
212. Shirani, K. Z. et al. Inappropriate vasopressin secretion (SIADH) in burned patients. J. Trauma 23, 217-224 (1983).
213. Walsh, C. H., Baylis, P. H. & Malins, J. M. Plasma arginine vasopressin in diabetic ketoacidosis. Diabetologia 16, 93-96 (1979).
214. Vokes, T. P., Aycinena, P. R. & Robertson, G. L. Effect of insulin on osmoregulation of vasopressin. Am. J. Physiol. 252, E538-E548 (1987).
215. Roch-Ramel, F., Diezi, J., Chomety, F., Michoud, P. & Peters, G. Disposal of large urea overloads by the rat kidney: A micropuncture study. Am. J. Physiol. 218, 1524-1532 (1970).
216. Addis, T. The osmotic work of the kidney and the treatment of glomerular nephritis. Trans. Assoc. Am. Phys. 55, 223-229 (1940).